CIA
KRYS icon

Capital Impact Advisors’s Krystal Biotech KRYS Stock Holding History

Capital Impact Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,343
Closed -$951K – 77
2024
Q1 		$951K Sell
5,343
-383
-7% -$53.2K 1.24% 29
2023
Q4 		$710K Hold
5,726
– – 0.93% 56
2023
Q3 		$664K Hold
5,726
– – 1.11% 36
2023
Q2 		$672K Hold
5,726
– – 0.74% 52
2023
Q1 		$458K Buy
5,726
+307
+6% +$24.1K 0.56% 79
2022
Q4 		$429K Buy
5,419
+269
+5% +$20K 0.42% 100
2022
Q3 		$395K Buy
5,150
+872
+20% +$63K 0.39% 107
2022
Q2 		$281K Buy
+4,278
New +$266K 0.26% 168

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Capital Impact Advisors's KRYS Position: Q2 2024 in Review

Capital Impact Advisors sold out of Krystal Biotech (KRYS) in Q2 2024, closing a stake of 5,343 shares — an estimated $951K sold.

Capital Impact Advisors first reported a position in KRYS in Q2 2022 and held it in 8 quarters. The position peaked at $951K in Q1 2024. 245 funds tracked by Wall St. Rank hold KRYS as of Q2 2024.

  • Capital Impact Advisors reported no remaining Krystal Biotech position as of Q2 2024 after selling out during the quarter.
  • Capital Impact Advisors sold 5,343 Krystal Biotech shares in Q2 2024, an estimated $951K.
  • Capital Impact Advisors first reported a position in Krystal Biotech in Q2 2022 and held it in 8 quarters.
  • Capital Impact Advisors's Krystal Biotech position peaked at $951K in Q1 2024.
  • 245 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2024.

Based on Capital Impact Advisors's 13F filing for Q2 2024, filed 16 Aug 2024.